Expression of Serum HMGB-1 in Patients with Secondary Hemo-phagocytic Lymphohistiocytosis and Its Clinical Significance.
- Author:
Dong-Jiao WANG
1
;
Ju-Juan WANG
1
;
Meng SONG
1
;
Xin GAO
1
;
Li-Min DUAN
1
;
Tian TIAN
1
;
Hong-Xia QIU
1
Author Information
- Publication Type:Journal Article
- MeSH: C-Reactive Protein; analysis; Case-Control Studies; Diagnosis, Differential; Enzyme-Linked Immunosorbent Assay; Fibrinogen; analysis; HMGB1 Protein; blood; Humans; Interleukin-2 Receptor alpha Subunit; blood; L-Lactate Dehydrogenase; blood; Leukocytes; Lymphohistiocytosis, Hemophagocytic; blood; Lymphoma; Sensitivity and Specificity; Treatment Outcome
- From: Journal of Experimental Hematology 2016;24(3):878-883
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the expression levels and clinical significance of serum high mobility group box 1 (HMGB-1) in patients with secondary hemophagocytic lymphohistiocytosis (sHLH).
METHODSSerum HMGB-1 levels were determined by using enzyme linked immunosorbent assays (ELISA) in 51 sHLH patients and 15 healthy contrlols. Other laboratory data, including soluble interleukin-2 receptor (sCD25), white blood cells (WBC), hemoglobin (Hb), platelet (Plt), fibrinogen (FIB), lactate dehydrogenase (LDH), triglyceride (TG), alanine transaminase (ALT), aspartate aminotransferase (AST), serum ferritin (SF), C reactive protein (CRP), and blood sedimentation rate (ESR) were also collected.
RESULTSSerum HMGB-1 levels in the newly diagnosed group were significantly higher than that in the control group (P<0.01). Serum HMGB-1 levels in the newly diagnosed lymphoma-associated HLH (LHLH) group were significantly higher than that in non-HLH group, including infection-associated HLH (IHLH) and autoimmune-associated HLH (AHLH) group (P<0.05); The serum HMGB-1 levels in the clinical remission group were significantly lower than that in the newly diagnosed group (P<0.05), however, serum HMGB-1 was not decreased significantly in the progression/relapsed group, compared with the newly diagnosed group (P>0.05). Serum HMGB-1 levels in newly diagnosed sHLH patients positively correlated with sCD25 (r=0.62, P<0.01) and ESR (r=0.55, P<0.05). The receiver operating characteristic curves (ROC) for serum HMGB-1 levels of sHLH patients and healthy controls produced a cutoff value at 15.3 µg/L, with its 90% sensitivity and 99% specificity, respectively. In addition, an optimal cutoff value for HMGB-1 was 27.4 µg/L in the patients LHLH and non-HLH (AHLH+IHLH) with 96% sensitivity and 81% specificity, separately.
CONCLUSIONSerum HMGB-1 levels possesses an important clinically significance for disease diagnosis, differential diagnosis, evaluation of nosographic activity and treatment efficacy in the patients with sHLH.